Ceftolozane-tazobactam pharmaceutical compositions

A method of treating an infection in a patient comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane and tazobactam in a ratio of 1,000 mg ceftolozane active per 500 mg of tazobactam active, and less than about 0.1% as detected by high performance liquid chromatography of a compound of formula (III)

A method of treating an infection in a patient selected from the group consisting of a complicated intra-abdominal infection or a complicated urinary tract infection, the method comprising intravenously administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane and tazobactam in a ratio of 1,000 mg ceftolozane active per 500 mg of tazobactam active, and less than about 0.1% as detected by HPLC of a compound of formula (III)

A method of treating an infection in a patient comprising administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane and tazobactam in a ratio of 1,000 mg ceftolozane active per 500 mg of tazobactam active, and less than about 0.1% as detected by high performance liquid chromatography of a compound detectable at a retention time relative to ceftolozane of 1.22 by high performance liquid chromatography using a Develosil column ODS-UG-5;

• 5 micrometers;
• 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C.

A method of treating an infection in a patient selected from the group consisting of a complicated intra-abdominal infection or a complicated urinary tract infection, the method comprising intravenously administering to the patient a therapeutically effective amount of a pharmaceutical composition comprising ceftolozane and tazobactam in a ratio of 1,000 mg ceftolozane active per 500 mg of tazobactam active, and less than about 0.1% as detected by high performance liquid chromatography of a compound detectable at a retention time relative to ceftolozane of 1.22 by high performance liquid chromatography using a Develosil column ODS-UG-5;

• 5 micrometers;
• 250×4.6 mm, a mobile phase of sodium perchlorate buffer solution (pH 2.5)/CH3CN 90:10 (v/v) at a 1.0 mL/min flow rate and oven temperature of 45° C., wherein the antibacterial pharmaceutical composition is obtained by a process comprising the step of lyophilizing a solution comprising ceftolozane in the absence of tazobactam.